Regency Capital Management Inc. DE Sells 3,416 Shares of Danaher Co. (NYSE:DHR)

Regency Capital Management Inc. DE cut its holdings in shares of Danaher Co. (NYSE:DHR) by 13.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,786 shares of the conglomerate’s stock after selling 3,416 shares during the quarter. Danaher makes up about 3.7% of Regency Capital Management Inc. DE’s investment portfolio, making the stock its 12th biggest position. Regency Capital Management Inc. DE’s holdings in Danaher were worth $5,693,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in DHR. Tsfg LLC lifted its holdings in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares in the last quarter. nVerses Capital LLC purchased a new position in shares of Danaher in the second quarter worth $25,000. CarsonAllaria Wealth Management Ltd. purchased a new position in shares of Danaher in the second quarter worth $25,000. Redmont Wealth Advisors LLC bought a new position in shares of Danaher during the first quarter worth $30,000. Finally, Richardson Financial Services Inc. purchased a new position in Danaher during the fourth quarter valued at $42,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Trading Up 0.9 %

DHR opened at $278.02 on Tuesday. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The company has a market capitalization of $205.93 billion, a P/E ratio of 47.12, a PEG ratio of 4.55 and a beta of 0.83. The stock’s fifty day moving average is $270.77 and its two-hundred day moving average is $258.06. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.05 earnings per share. Analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s payout ratio is 18.31%.

Insider Buying and Selling

In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock valued at $11,042,433 over the last 90 days. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on DHR. Wells Fargo & Company began coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Stifel Nicolaus increased their price target on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. The Goldman Sachs Group lifted their price objective on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Royal Bank of Canada reiterated an “outperform” rating and set a $300.00 target price on shares of Danaher in a research report on Friday, September 6th. Finally, Robert W. Baird boosted their price target on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.